Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01772771 · ClinicalTrials.gov registry record
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
A clinical trial of Melanoma and Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 12,000
- Enrollment target
- 1
- Study location
NCT01772771 is a study of Melanoma and Malignant Solid Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 12,000 participants, above the 661-participant average among 266 other Melanoma trials with a reported enrollment target (1715% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01772771, a study of Melanoma and Malignant Solid Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 12,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be most relevant to patients. Researchers may also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Medical Chart Review
- OTHER Genetic Testing
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,000 participants |
| Start Date | 2012-03-01 |
| Est. Completion | 2033-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01772771
The ClinicalTrials.gov registry entry for NCT01772771 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 12,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 661-participant average among 266 other Melanoma trials with a reported enrollment target (1715% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT01772771 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01772771 about?
NCT01772771 is a clinical study titled "Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program". This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be ...
What is the current status of trial NCT01772771?
This trial is currently recruiting. The enrollment target is 12,000 participants. The study started on 2012-03-01. Estimated completion is 2033-03-01.
What conditions does trial NCT01772771 study?
This clinical trial studies the following conditions: Melanoma, Malignant Solid Neoplasm, Sarcoma, Hematopoietic and Lymphoid Cell Neoplasm, Glioma.
What interventions are being tested in trial NCT01772771?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Medical Chart Review (OTHER), Genetic Testing (OTHER).
Who is sponsoring clinical trial NCT01772771?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01772771 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.